A landmark study by Buzzai et al. [75] used the paired isogenic colon cancer cell lines HCT116 p53+/+ and HCT116 p53−/− to test systemic treatment with metformin (250 mg kg−1 administered by daily i.p. injections). This evidence concerns the gene TP53 and malignant colon neoplasm.